Health Condition 1: C00-C14- Malignant neoplasms of lip, oral cavity and pharynx
Conditions
Interventions
Intervention1: Nil: Nil
Intervention2: Nil: Nil
Control Intervention1: Nil: Nil
Sponsors
MSD Pharmaceuticals Pvt Ltd
Eligibility
Inclusion criteria
Inclusion criteria: 1.Patients aged greater than or equal to 18 years of age at the time of LA HNSCC diagnosis. 2.Patients of either sex with histopathological confirmed diagnosis (biopsy-proven) of HNSCC involving all types of oral cancers (including lip & oral, base of tongue and others), laryngeal, oropharyngeal, and hypopharyngeal cancers. 3.Patients diagnosed with LA HNSCC (Stage III to Stage IVB lip & oral, HPV negative laryngeal, oropharyngeal, and hypopharyngeal cancers or Stage III HPV positive HNSCC (excluding nasopharyngeal cancers) between January 01, 2018, and December 31, 2022 (patient identification period). 4.Patients prescribed with first therapy for the treatment of treatment na ve LA HNSCC. 5.Patients with availability of minimum one year follow-up data post initiation of first therapy for LA HNSCC management 6.Patients with greater than or equal to 5 visits at the selected sites for enrollment.
Exclusion criteria
Exclusion criteria: 1.Patient with nasopharyngeal cancers of any etiology. 2.Patients with malignancies involving paranasal sinuses, salivary glands, or thyroid. 3.Patient who has participated in any interventional clinical trials, for the management of LA HNSCC during the study period. 4.Patients who did not receive any definitive treatment after diagnosis due to refusal of treatment plan. 5.Patients with malignant diseases other than LA HNSCC, diagnosed within 5 years prior to the diagnosis of LA HNSCC. 6.Patients who received treatment indicated for another primary cancer between January 01,2018 and December 31, 2022. 7.Patients who received immune checkpoint inhibitors for LA HNSCC disease.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Distribution of 1st treatments - Time from initial LA HNSCC diagnosis to 1st treatment initiation - Percentage of patients treated with next treatment - Surgery rate - Percentage of patients with induction chemotherapy, induction drugs used, schemes of induction drugs -Percentage of patients with neoadjuvant chemotherapy, neoadjuvant drugs used, schemes of neoadjuvant drugs -Percentage of patients with concurrent pharmacological treatment, concurrent drugs used, schemes of concurrent drugs -Percentage of patients in each of the different treatment sequences foundTimepoint: From site initiation to end of follow up (approximately 2 years) | — |
Secondary
| Measure | Time frame |
|---|---|
| -Proportion of patients being tested for HPV status, proportion of patients positive for HPV -Proportion of patients being tested for PD-L1 status, proportion of patients positive for PD-L1 -Percentage of cases evaluated in tumor boardTimepoint: From site initiation to end of follow up (approximately 2 years) | — |
Countries
India
Contacts
Public ContactDr Ajay Patil
MSD Pharmaceuticals Pvt Ltd
Outcome results
None listed